LEN vs TBPH · rev $34.19B vs P/E 7.5, rev $18.8M
LEN (LEN) versus Theravance Biopharma Inc (TBPH) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported TBPH revenue for 2024-12-31 was $18.8M. Net income was -$15.5M. Revenue was up 11.2% from 2024-09-30 to 2024-12-31. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
LEN currently screens at market cap $0. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
Not investment advice. Open the LEN and TBPH stock pages for the full models.
Not investment advice.